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Prevalence and architecture of de novo mutations in 
developmental disorders
The Deciphering Developmental Disorders Study
Summary
Individuals with severe, undiagnosed developmental disorders (DDs) are enriched for damaging de 
novo mutations (DNMs) in developmentally important genes. We exome sequenced 4,293 families 
with individuals with DDs, and meta-analysed these data with another 3,287 individuals with 
similar disorders. We show that the most significant factors influencing the diagnostic yield of 
DNMs are the sex of the affected individual, the relatedness of their parents, whether close 
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relatives are affected and parental ages. We identified 94 genes enriched for damaging DNMs, 
including 14 without previous compelling evidence. We have characterised the phenotypic 
diversity among these disorders. We estimate that 42% of our cohort carry pathogenic DNMs in 
coding sequences, and approximately half disrupt gene function, with the remainder resulting in 
altered-function. We estimate that developmental disorders caused by DNMs have an average birth 
prevalence of 1 in 213 to 1 in 448, depending on parental age. Given current global demographics, 
this equates to almost 400,000 children born per year.
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Approximately 2-5% of children are born with major congenital malformations and/or 
manifest severe neurodevelopmental disorders during childhood1,2. While diverse 
mechanisms can cause such developmental disorders, including gestational infection and 
maternal alcohol consumption, damaging genetic variation in developmentally important 
genes has a major contribution. Several recent studies have identified a substantial causal 
role for DNMs not present in either parent3–16. Despite the identification of many 
developmental disorders caused by DNMs, it is generally accepted that many more such 
disorders await discovery15, and the overall contribution of DNMs to developmental 
disorders is not known. Moreover, some pathogenic DNMs completely ablate the function of 
the encoded protein, whereas others alter the function of the encoded protein17; the relative 
contributions of these two mechanistic classes is also not known.
We recruited 4,293 individuals to the Deciphering Developmental Disorders (DDD) study15 
via genetics services of the UK National Health Service and Republic of Ireland. Each of 
these individuals was referred with a severe undiagnosed developmental disorder and most 
were the only affected family member. Most (81%) individuals had been screened for large 
pathogenic deletions and duplications. We systematically phenotyped these individuals and 
sequenced the exomes of these individuals and their parents. Growth measurements, family 
history, and developmental milestones were collected, and detailed clinical phenotypes were 
captured using Human Phenotype Ontology (HPO) terms. Analyses of 1,133 of these trios 
were described previously15,18. We generated a high sensitivity set of 8,361 candidate 
DNMs in coding or splicing sequence (mean of 1.95 DNMs per proband), while removing 
systematic erroneous calls (Supplementary Table 1). This rate of candidate DNMs per 
proband is higher than other studies3–15, because we wish to maintain high sensitivity, and 
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can address lower specificity via subsequent validation. 1,624 genes contained two or more 
DNMs in unrelated individuals.
Twenty-three percent of individuals had likely pathogenic protein-truncating or missense 
DNMs within the clinically curated set of genes robustly associated with dominant 
developmental disorders18. We investigated factors associated with whether an individual 
had a likely pathogenic DNM in these curated genes (Figure 1a, b, Supplementary Table 1). 
We observed that males had a lower chance of carrying a likely pathogenic DNM (P = 1.6 x 
10-4; OR 0.75, 0.65 - 0.87 95% CI), as has also been observed in autism19. We also 
observed increased likelihood of having a pathogenic DNM with the extent of speech delay 
(P = 0.00115), but not other indicators of severity relative to the rest of the cohort. 
Individuals with other affected family members were less likely to have pathogenic DNMs 
(affected siblings: P = 7.3 x 10-18, affected parents: P = 5.7 x 10-9), and individuals who 
were from self-declared consanguineous unions were less likely to have a pathogenic DNM 
(P = 8.0 x 10-11). Furthermore, the total genomic extent of autozygosity (due to parental 
relatedness) was negatively correlated with the likelihood of having a pathogenic DNM (P = 
1.7 x 10-7), for every log10 increase in autozygous length, the probability of having a 
pathogenic DNM dropped by 7.5%, likely due to increasing burden of recessive causation 
(Figure 1c). Nonetheless, 6% of individuals with autozygosity equivalent to a first cousin 
union or greater had a plausibly pathogenic DNM, underscoring the importance of 
considering de novo causation in all families.
Paternal age has been shown to be the primary factor influencing the number of DNMs in a 
child20,21, and thus is expected to be a risk factor for pathogenic DNMs. Paternal age was 
only weakly associated with likelihood of having a pathogenic DNM (P = 0.016). However, 
focusing on the minority of DNMs that were truncating and missense variants in known DD-
associated genes limits our power to detect such an effect. Analysing all 8,409 high 
confidence exonic and intronic autosomal DNMs confirmed a strong paternal age effect (P = 
1.4 x 10-10, 1.53 DNMs/year, 1.07-2.01 95% CI), as well as highlighting a weaker, 
independent, maternal age effect (P = 0.0019, 0.86 DNMs/year, 0.32-1.40 95% CI, Figure 
1d,e), as has recently been described in whole genome analyses22. These genome-wide 
estimates were scaled from exome-based estimates, of 0.0306 DNMs/year paternal effect 
and 0.0172 DNMs/year maternal effect.
We identified genes significantly enriched for damaging DNMs by comparing the observed 
gene-wise DNM count to that expected under a null mutation model23, as described 
previously15. We combined this analysis with 4,224 published DNMs in 3,287 affected 
individuals from thirteen exome or genome sequencing studies (Supplementary Table 2)3–
14 that exhibited a similar excess of DNMs in our curated set of DD-associated genes 
(Extended Data Figure 1). We found 93 genes with genome-wide significance (P < 5 × 10-7, 
Figure 2), 80 of which had prior evidence of DD-association (Supplementary Table 3). We 
have developed visual summaries of the phenotypes associated with each gene to facilitate 
clinical use. In addition, we created anonymised average face images from individuals with 
DNMs in genome-wide significant genes (Figure 2) from ordinary (2D) clinical photos using 
previously validated software24. These images highlight facial dysmorphologies specific to 
certain genes. After careful review by two experienced clinical geneticists, average face 
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images for twelve genes were determined to be truly anonymised and of sufficient quality.To 
assess any increase in power to detect novel DD-associated genes, we excluded individuals 
with likely pathogenic variants in known DD-associated genes15, leaving 3,158 probands 
from our cohort, along with 2,955 probands from the meta-analysis studies. In this subset, 
fourteen genes for which no statistically-compelling prior evidence for DD causation was 
available achieved genome-wide significance: CDK13, CHD4, CNOT3, CSNK2A1, GNAI1, 
KCNQ3, MSL3, PPM1D, PUF60, QRICH1, SET, SUV420H1, TCF20, and ZBTB18 (P < 5 
x 10-7, Table 1, Extended Data Figure 4). The clinical features associated with these newly 
confirmed disorders are summarised in Extended Data Figure 2, Extended Data Figure 3 and 
Supplementary Information. QRICH1 would not achieve genome-wide significance without 
excluding individuals with likely pathogenic variants in DD-associated genes. In addition to 
discovering novel DD-associated genes, we identified several new disorders linked to known 
DD-associated genes, but with different modes of inheritance or molecular mechanisms. We 
found USP9X and ZC4H2 had a genome-wide significant excess of DNMs in female 
probands, indicating these genes have X-linked dominant modes of inheritance in addition to 
previously reported X-linked recessive mode of inheritance in males25,26. In addition, we 
found truncating mutations in SMC1A were strongly associated with a novel seizure 
disorder (P = 6.5 x 10-19), while in-frame/missense mutations in SMC1A with dominant 
negative effects27 are a known cause of Cornelia de Lange Syndrome (CdLS). Individuals 
with truncating mutations in SMC1A lacked the characteristic facial dysmorphology of 
CdLS.
We then explored two approaches for integrating phenotypic data into disease gene 
association: statistical assessment of Human Phenotype Ontology (HPO) term similarity 
between individuals sharing candidate DNMs in the same gene (as we described 
previously28) and phenotypic stratification based on specific clinical characteristics. 
Combining genetic evidence and HPO term similarity increased the significance of some 
known DD-associated genes. However, significance decreased for a larger number of genes 
causing severe DD but associated with non discriminative HPO terms (Extended Data Figure 
5a). Although we did not incorporate categorical phenotypic similarity in the gene discovery 
analyses described above, the systematic acquisition of phenotypic data on affected 
individuals within DDD enabled aggregate representations to be created for each gene 
achieving genome-wide significance. We present these in the form of icon-based summaries 
of growth and developmental milestones (PhenIcons), heatmaps of the recurrently coded 
HPO terms and, where photos for at least ten children with mutations in the same gene were 
available, an anonymised average facial representation (Supplementary Information).
Twenty percent of individuals had HPO terms which indicated seizures and/or epilepsy. We 
compared analysis within this phenotypically stratified group with gene-wise analyses of the 
entire cohort, to see if it increased power to detect known seizure-associated genes 
(Extended Data Figure 5b). Fifteen seizure-associated genes were genome-wide significant 
in both the seizure-only and the entire-cohort analyses. Nine seizure-associated genes were 
genome-wide significant in the entire cohort but not in the seizure subset. Of the 285 
individuals with truncating or missense DNMs in known seizure-associated genes, 56% of 
individuals had no coded terms related to seizures/epilepsy. These findings suggest that the 
power of increased sample size far outweighs specific phenotypic expressivity due to the 
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shared genetic etiology between individuals with and without epilepsy in our cohort. Despite 
this, nearly three times as many individuals with seizures had a DNM in a seizure-associated 
gene compared to individuals without seizures (Extended Data Figure 5c). At matched 
sample sizes, more genes exceeded genomewide significance in seizure samples than in 
unstratified samples (Extended Data Figure 5d). This highlights the cost-benefit of recruiting 
a phenotypically more homogenous cohort.
The large number of genome-wide significant genes identified in the analyses above allows 
us to compare empirically different experimental strategies for novel gene discovery in a 
genetically heterogeneous cohort. We compared the power of exome and genome 
sequencing to detect genome-wide significant genes, assuming that budget and not samples 
are limiting, under different scenarios of cost ratios and sensitivity ratios (Extended Data 
Figure 6a). At current cost ratios (exome costs 30-40% of a genome) and with a plausible 
sensitivity differential (genome detects 5% more exonic variants than exome29) exome 
sequencing detects more than twice as many genome-wide significant genes. These 
empirical estimates were consistent with power simulations for identifying dominant loss-of-
function genes (Extended Data Figure 6b). In summary, while genome sequencing gives 
greatest sensitivity to detect pathogenic variation in a single individual (or outside of the 
coding region), exome sequencing is more powerful for novel disease gene discovery (and, 
analogously, likely delivers lower cost per diagnosis currently).
Our previous simulations suggested that analysis of a cohort of 4,293 DDD families ought to 
be able to detect approximately half of all haploinsufficient DD-associated genes at genome-
wide significance15. Empirically, we have identified 47% (50/107) of haploinsufficient 
genes previously robustly associated with neurodevelopmental disorders18. We hypothesised 
that genetic testing prior to recruitment into our study may have depleted the cohort of the 
most clinically recognisable disorders. Indeed, we observed that the genes associated with 
the most clinically recognisable disorders were associated with a significant, three-fold 
lower enrichment of truncating DNMs than other DD-associated genes (~40-fold enrichment 
vs ~120-fold enrichment, Figure 3a). Removing these most recognisable disorders from the 
analysis, we identified 55% (42/76) of the remaining haploinsufficient DD-associated genes. 
The known DD-associated haploinsufficient genes that did not reach genome-wide 
significance were clearly enriched for those with lower mutability, which we would expect 
to lower power to detect in our analyses. We identified DD-associated genes (e.g. NRXN2) 
with high mutability, low clinical recognisability and yet no signal of enrichment for DNMs 
in our cohort, as assessed by ΔAIC (Extended Data Figure 7, Supplementary Table 4). Our 
analyses call into question whether these genes really are associated with haploinsufficient 
neurodevelopmental disorders and highlights the potential for well-powered gene discovery 
analyses to refute prior credence regarding disease gene associations or prior inferences 
regarding an underlying haploinsufficient mechanism.
We estimated the likely prevalence of pathogenic missense and truncating DNMs within our 
cohort by increasing the stringency of called DNMs until the observed synonymous DNMs 
equated that expected under the null mutation model (Extended Data Figure 8a), then 
quantifying the excess of observed missense and truncating DNMs across all genes (Figure 
3b). We observed an excess of 576 truncating and 1,220 missense mutations, suggesting 
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41.8% (1,796/4,293) of the cohort has a pathogenic DNM. This estimate of the number of 
excess missense and truncating DNMs in our cohort is robust to varying the stringency of 
DNM calling (Extended Data Figure 8b). The vast majority of synonymous DNMs are likely 
to be benign, as evidenced by them being distributed uniformly (Figure 3d) among genes 
irrespective of their tolerance of truncating variation in the general population (as quantified 
by the probability of being LoF-intolerant (pLI) metric30). By contrast, missense and 
truncating DNMs are significantly enriched in genes with the highest probabilities of being 
intolerant of truncating variation (Figure 3d). The pLI-based distributions were similar to 
distributions which used functional constraint (Extended Data Figure 9)31. Only 51% 
(923/1,796) of these excess missense and truncating DNMs are located in DD-associated 
dominant genes, with the remainder likely to affect genes not yet associated with DDs. A 
much higher proportion of the excess truncating DNMs (71%) than missense DNMs (42%) 
affected known DD-associated genes. This suggests that whereas most haploinsufficient 
DD-associated genes have already been identified, many DD-associated genes characterised 
by pathogenic missense DNMs remain to be discovered.
Understanding the mechanism of action of a monogenic disorder is an important prerequisite 
for designing therapeutic strategies32. We sought to estimate the relative proportion of 
altered-function and loss-of-function mechanisms among the excess DNMs in our cohort, by 
assuming that the vast majority of truncating mutations operate by a loss-of-function 
mechanism and using two independent approaches to estimate the relative contribution of 
the two mechanisms among the excess missense DNMs (Methods). First, we used the 
observed ratio of truncating and missense DNMs within haploinsufficient DD-associated 
genes to estimate the proportion of the excess missense DNMs that likely act by loss-of-
function (Figure 3c). This approach estimated that 59% (55 - 64% 95% CI) of excess 
missense and truncating DNMs operate by loss-of-function, and 41% by altered-function. 
Second, we took advantage of the different population genetic characteristics of known 
altered-function and loss-of-function DD-associated genes. Specifically, we observed that 
these two classes of DD-associated genes are differentially depleted of truncating variation 
in individuals without overt developmental disorders (pLI metric30). We modelled the 
observed pLI distribution of excess missense DNMs as a mixture of the pLI distributions of 
known altered-function and loss-of-function DD-associated genes (Figure 3e, f), and 
estimated that 63% (50 - 76% 95% CI) of excess missense DNMs likely act by altered-
function mechanisms. Incorporating the truncating DNMs operating by a loss-of-function 
mechanism, this approach estimated that 57% (48 - 66% 95% CI) of excess missense and 
truncating DNMs operate by loss-of-function and 43% by altered-function.
We estimated the birth prevalence of monoallelic developmental disorders by using the 
germline mutation model to calculate the expected cumulative germline mutation rate of 
truncating DNMs in haploinsufficient DD-associated genes and scaling this upwards based 
on the composition of excess DNMs in the DDD cohort described above (see Methods), 
correcting for disorders that are under-represented in our cohort as a result of prior genetic 
testing (e.g. clinically-recognisable disorders and large pathogenic CNVs identified by prior 
chromosomal microarray analysis). This gives a mean prevalence estimate of 0.34% 
(0.31-0.37 95% CI), or 1 in 295 births. By factoring in the paternal and maternal age effects 
on the mutation rate (Figure 1) we modelled age-specific estimates of birth prevalence 
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(Figure 4) that range from 1 in 448 (both mother and father aged 20) to 1 in 213 (both 
mother and father aged 45). Assuming a yearly global birth rate of 18.6 live births/1000 
individuals, and a mean age when giving birth of 26.6 years, nearly 400,000 of the 140 
million annual births will have a developmental disorder caused by a DNM.
In summary, we have shown that de novo mutations account for approximately half of the 
genetic architecture of severe developmental disorders, and are split roughly equally 
between loss-of-function and altered-function. Whereas most haploinsufficient DD-
associated genes have already been identified, currently many activating and dominant 
negative DD-associated genes have eluded discovery. This elusiveness likely results from 
these disorders being individually rarer, being caused by a relatively small number of 
missense mutations within each gene. It would be valuable to estimate the penetrance of de 
novo mutations in the genes we identified exceeding genome-wide significance, but we 
cannot formally assess penetrance with our data. Future evaluations could integrate 
depletion of damaging variation in large healthy populations with patterns of segregation in 
affected families. Discovery of the remaining dominant developmental disorders requires 
larger studies and novel, more powerful, analytical strategies for disease-gene association 
that leverage gene-specific patterns of population variation, specifically the observed 
depletion of damaging variation. The integration of accurate and complete quantitative and 
categorical phenotypic data into the analysis will improve the power to identify ultrarare DD 
with distinctive clinical presentations. We have estimated the mean birth prevalence of 
dominant monogenic developmental disorders to be around 1 in 295, which is greater than 
the combined impact of trisomies 13, 18 and 2133 and highlights the cumulative population 
morbidity and mortality imposed by these individually rare disorders.
Methods
Family recruitment
At 24 clinical genetics centers within the United Kingdom (UK) National Health Service 
and the Republic of Ireland, 4,293 patients with severe, undiagnosed developmental 
disorders and their parents (4,125 families) were recruited and systematically phenotyped. 
The study has UK Research Ethics Committee approval (10/H0305/83, granted by the 
Cambridge South Research Ethics Committee and GEN/284/12, granted by the Republic of 
Ireland Research Ethics Committee). Families gave informed consent for participation.
Clinical data (growth measurements, family history, developmental milestones, etc.) were 
collected using a standard restricted-term questionnaire within DECIPHER34, and detailed 
developmental phenotypes for the individuals were entered using Human Phenotype 
Ontology (HPO) terms35. Saliva samples for the whole family and blood-extracted DNA 
samples for the probands were collected, processed and quality controlled as previously 
described15.
Exome sequencing
Genomic DNA (approximately 1 μg) was fragmented to an average size of 150 base-pairs 
(bp) and subjected to DNA library creation using established Illumina paired-end protocols. 
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Adaptor-ligated libraries were amplified and indexed via polymerase chain reaction (PCR). 
A portion of each library was used to create an equimolar pool comprising eight indexed 
libraries. Each pool was hybridized to SureSelect ribonucleic acid (RNA) baits (Agilent 
Human All-Exon V3 Plus with custom ELID C0338371 and Agilent Human All-Exon V5 
Plus with custom ELID C0338371) and sequence targets were captured and amplified in 
accordance with the manufacturer's recommendations. Enriched libraries were subjected to 
75-base paired-end sequencing (Illumina HiSeq) following the manufacturer's instructions.
Alignment and calling single nucleotide variants, insertions and deletions
Mapping of short-read sequences for each sequencing lanelet was carried out using the 
Burrows-Wheeler Aligner (BWA; version 0.59)36 backtrack algorithm with the GRCh37 
1000 Genomes Project phase 2 reference (also known as hs37d5). Sample-level BAM 
improvement was carried out using the Genome Analysis Toolkit (GATK; version 3.1.1)37 
and SAMtools (version 0.1.19)38. This consisted of a realignment of reads around known 
and discovered indels followed by base quality score recalibration (BQSR), with both steps 
performed using GATK. Lastly, SAMtools calmd was applied and indexes were created.
Known indels for realignment were taken from the Mills Devine and 1000 Genomes Project 
Gold set and the 1000 Genomes Project phase low-coverage set, both part of the GATK 
resource bundle (version 2.2). Known variants for BQSR were taken from dbSNP 137, also 
part of the GATK resource bundle. Finally, single nucleotide variants (SNVs) and indels 
were called using the GATK HaplotypeCaller (version 3.2.2); this was run in multisample 
calling mode using the complete data set. GATK Variant Quality Score Recalibration 
(VQSR) was then computed on the whole data set and applied to the individual-sample 
variant calling format (VCF) files. DeNovoGear (version 0.54)39 was used to detect SNV, 
insertion and deletion de novo mutations (DNMs) from child and parental exome data (BAM 
files).
Variant annotation
Variants in the VCF were annotated with minor allele frequency (MAF) data from a variety 
of different sources. The MAF annotations used included data from four different 
populations of the 1000 Genomes Project40 (AMR, ASN, AFR and EUR), the UK10K 
cohort, the NHLBI GO Exome Sequencing Project (ESP), the Non-Finnish European (NFE) 
subset of the Exome Aggregation Consortium (ExAC) and an internal allele frequency 
generated using unaffected parents from the cohort.
Variants in the VCF were annotated with Ensembl Variant Effect Predictor (VEP)41 based 
on Ensembl gene build 76. The transcript with the most severe consequence was selected 
and all associated VEP annotations were based on the predicted effect of the variant on that 
particular transcript; where multiple transcripts shared the same most severe consequence, 
the canonical or longest was selected. We included an additional consequence for variants at 
the last base of an exon before an intron, where the final base is a guanine, since these 
variants appear to be as damaging as a splice donor variant28.
We categorized variants into three classes by VEP consequence:
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1. protein-truncating variants (PTV): splice donor, splice acceptor, stop gained, 
frameshift, initiator codon, and conserved exon terminus variant.
2. missense variants: missense, stop lost, inframe deletion, inframe insertion, 
coding sequence, and protein altering variant.
3. silent variants: synonymous.
De novo mutation filtering
We filtered candidate DNM calls to reduce the false positive rate but maximize sensitivity, 
based on prior results from experimental validation by capillary sequencing of candidate 
DNMs15. Candidate DNMs were excluded if not called by GATK in the child, or called in 
either parent, or if they had a maximum MAF greater than 0.01. Candidate DNMs were 
excluded when the forward and reverse coverage differed between reference and alternative 
alleles, defined as P < 10-3 from a Fisher’ s exact test of coverage from orientation by allele 
summed across the child and parents.
Candidate DNMs were also excluded if they met two of the three following three criteria: 1) 
an excess of parental alternative alleles within the cohort at the DNMs position, defined as P 
< 10-3 under a one-sided binomial test given an expected error rate of 0.002 and the 
cumulative parental depth; 2) an excess of alternative alleles within the cohort in DNMs in a 
gene, defined as P < 10-3 under a one-sided binomial test given an expected error rate of 
0.002 and the cumulative depth, or 3) both parents had one or more reads supporting the 
alternative allele.
If, after filtering, more than one variant was observed in a given gene for a particular trio, 
only the variant with the highest predicted functional impact was kept (protein truncating > 
missense > silent).
De novo mutation validation
For candidate DNMs of interest, primers were designed to amplify 150-250 bp products 
centered around the site of interest. Default primer3 design settings were used with the 
following adjustments: GC clamp = 1, human mispriming library used. Site-specific primers 
were tailed with Illumina adapter sequences. PCR products were generated with JumpStart 
AccuTaq LA DNA polymerase (Sigma Aldrich), using 40 ng genomic DNA as template. 
Amplicons were tagged with Illumina PCR primers along with unique barcodes enabling 
multiplexing of 96 samples. Barcodes were incorporated using Kapa HiFi mastermix (Kapa 
Biosystems). Samples were pooled and sequenced down one lane of the Illumina MiSeq, 
using 250 bp paired end reads. An in-house analysis pipeline extracted the read count per 
site and classified inheritance status per variant using a maximum likelihood approach (see 
Supplementary Note).
Individuals with likely pathogenic variants
We previously screened 1,133 individuals for variants that contribute to their disorder15,18. 
All candidate variants in the 1,133 individuals were reviewed by consultant clinical 
geneticists for relevance to the individuals’  phenotypes. Most diagnosable pathogenic 
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variants occurred de novo in dominant genes, but a small proportion also occurred in 
recessive genes or under other inheritance modes. DNMs within dominant DD-associated 
genes were very likely to be classified as the pathogenic variant for the individuals’  disorder. 
Due to the time required to review individuals and their candidate variants, we did not 
conduct a similar review in the remainder of the 4,293 individuals. Instead we defined likely 
pathogenic variants as candidate DNMs found in autosomal and X-linked dominant DD-
associated genes, or candidate DNMs found in hemizygous DD-associated genes in males. 
1,136 individuals in the 4,293 cohort had variants either previously classified as 
pathogenic15,18, or had a likely pathogenic DNM.
Gene-wise assessment of DNM significance
Gene-specific germline mutation rates for different functional classes were computed15,23 
for the longest transcript in the union of transcripts overlapping the observed DNMs in that 
gene. We evaluated the gene-specific enrichment of PTV and missense DNMs by computing 
its statistical significance under a null hypothesis of the expected number of DNMs given the 
gene-specific mutation rate and the number of considered chromosomes23.
We also assessed clustering of missense DNMs within genes15, as expected for DNMs 
operating by activating or dominant negative mechanisms. We did this by calculating 
simulated dispersions of the observed number of DNMs within the gene. The probability of 
simulating a DNM at a specific codon was weighted by the trinucleotide sequence-
context15,23. This allowed us to estimate the probability of the observed degree of 
clustering given the null model of random mutations.
Fisher’ s method was used to combine the significance testing of missense + PTV DNM 
enrichment and missense DNM clustering. We defined a gene as significantly enriched for 
DNMs if the PTV enrichment P-value or the combined missense P-value less than 7 × 10-7, 
which represents a Bonferroni corrected P-value of 0.05 adjusted for 4 × 18500 tests (2 × 
consequence classes tested × protein coding genes).
Composite face generation
Families were given the option to have photographs of the affected individual(s) uploaded 
within DECIPHER34. Using images of individuals with DNMs in the same gene we 
generated de-identified realistic average faces (composite faces). Faces were detected using 
a discriminately trained deformable part model detector42. The annotation algorithm 
identified a set of 36 landmarks per detected face43 and was trained on a manually 
annotated dataset of 3100 images24. The average face mesh was created by the Delaunay 
triangulation of the average constellation of facial landmarks for all patients with a shared 
genetic disorder.
The averaging algorithm is sensitive to left-right facial asymmetries across multiple patients. 
For this purpose, we use a template constellation of landmarks based on the average 
constellations of 2000 healthy individuals24. For each patient, we align the constellation of 
landmarks to the template with respect to the points along the middle of the face and 
compute the Euclidean distances between each landmark and its corresponding pair on the 
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template. The faces are mirrored such that the half of the face with the greater difference is 
always on the same side.
The dataset used for this work may contain multiple photos for one patient. To avoid biasing 
the average face mesh towards these individuals, we computed an average face for each 
patient and use these personal averages to compute the final average face. Finally, to avoid 
any image in the composite dominating from variance in illumination between images, we 
normalised the intensities of pixel values within the face to an average value across all faces 
in each average. The composite faces were assessed visually to confirm successful ablation 
of any individually identifiable features. Visual assessment of the composite photograph by 
two experienced clinical geneticists, alongside the individual patient photos, was performed 
for all 93 genome-wide significant DD-associated genes for which clinical photos were 
available for more than one patient, to remove potentially identifiable composite faces as 
well as quality control on the automated composite face generation process. Eighty-one 
composite faces were excluded leaving the twelve de-identified composite faces that are 
shown in Figure 2 and Extended Data Figure 3. Each of the twelve composite faces that 
passed de-identification and quality control was generated from photos of ten or more 
patients.
Assessing power of incorporating phenotypic information
We previously described a method to assess phenotypic similarity by HPO terms among 
groups of individuals sharing genetic defects in the same gene28. We examined whether 
incorporating this statistical test improved our ability to identify dominant genes at genome-
wide significance. Per gene, we tested the phenotypic similarity of individuals with DNMs 
in the gene. We combined the phenotypic similarity P-value with the genotypic P-value per 
gene (the minimum P-value from the DDD-only and meta-analysis) using Fisher’ s method. 
We examined the distribution of differences in P-value between tests without the phenotypic 
similarity P-value and tests that incorporated the phenotypic similarity P-value.
Many (854, 20%) of the DDD cohort experience seizures. We investigated whether testing 
within the subset of individuals with seizures improved our ability to find associations for 
seizure specific genes. A list of 102 seizure-associated genes was curated from three 
sources, a gene panel for Ohtahara syndrome, a currently used clinical gene panel for 
epilepsy and a panel derived from DD-associated genes18. The P-values from the seizure 
subset were compared to P-values from the complete cohort.
Assessing power of exome vs genome sequencing
We compared the expected power of exome sequencing versus genome sequencing to 
identify disease genes. Within the DDD cohort, 55 dominant DD-associated genes achieve 
genome-wide significance when testing for enrichment of DNMs within genes. We did not 
incorporate missense DNM clustering due to the large computational requirements for 
assessing clustering in many replicates.
We assumed a cost of 1,000 USD per individual for genome sequencing. We allowed the 
cost of exome sequencing to vary relative to genome sequencing, from 10-100%. We 
calculated the number of trios that could be sequenced under these scenarios. Estimates of 
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the improved power of genome sequencing to detect DNMs in the coding sequence are 
around 1.05-fold29 and we increased the number of trios by 1.0–1.2-fold to allow this.
We sampled as many individuals from our cohort as the number of trios and counted which 
of the 55 DD-associated genes still achieved genome-wide significance for DNM 
enrichment. We ran 1000 simulations of each condition and obtained the mean number of 
genome-wide significant genes for each condition.
Associations with presence of likely pathogenic de novo mutations
We tested whether phenotypes were associated with the likelihood of having a likely 
pathogenic DNM. We analysed all collected phenotypes which could be coded in either a 
binary or quantitative format. Categorical phenotypes (e.g. sex coded as male or female) 
were tested by Fisher’ s exact test while quantitative phenotypes (e.g. duration of gestation 
coded in weeks) were tested with logistic regression, using sex as a covariate.
We investigated whether having autozygous regions affected the likelihood of having a 
diagnostic DNM. Autozygous regions were determined from genotypes in every individual, 
to obtain the total length per individual. We fitted a logistic regression for the total length of 
autozygous regions on whether individuals had a likely pathogenic DNM. To illustrate the 
relationship between length of autozygosity and the occurrence of a likely pathogenic DNM, 
we grouped the individuals by length and plotted the proportion of individuals in each group 
with a DNM against the median length of the group.
The effects of parental age on the number of DNMs were assessed using 8,409 high 
confidence (posterior probability of DNM > 0.5) unphased coding and noncoding DNMs in 
4,293 individuals. A Poisson multiple regression was fit on the number of DNMs in each 
individual with both maternal and paternal age at the child’ s birth as covariates. The model 
was fit with the identity link and allowed for overdispersion. This model used exome-based 
DNMs, and the analysis was scaled to the whole genome by multiplying the coefficients by 
a factor of 50, based on ~2% of the genome being well covered in our data (exons + introns).
Excess of de novo mutations by consequence
We identified the threshold for posterior probability of DNM at which the number of 
observed candidate synonymous DNMs equalled the number of expected synonymous 
DNMs. Candidate DNMs with scores below this threshold were excluded. We also examined 
the likely sensitivity and specificity of this threshold based on validation results for DNMs 
within a previous publication15 in which comprehensive experimental validation was 
performed on 1,133 trios that comprise a subset of the families analysed here.
The numbers of expected DNMs per gene were calculated per consequence from expected 
mutation rates per gene and the 2,407 male and 1,886 females in the cohort. We calculated 
the excess of DNMs for missense and PTVs as the ratio of numbers of observed DNMs 
versus expected DNMs, as well as the difference of observed DNMs minus expected DNMs.
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Ascertainment bias within dominant neurodevelopmental genes
We identified 150 autosomal dominant haploinsufficient genes that affect neurodevelopment 
within our curated developmental disorder gene set. Genes affecting neurodevelopment were 
identified where the affected organs included the brain, or where HPO phenotypes linked to 
defects in the gene included either an abnormality of brain morphology (HP:0012443) or 
cognitive impairment (HP:0100543) term.
The 150 genes were classified for ease of clinical recognition of the syndrome from gene 
defects by two consultant clinical geneticists. Genes were rated from 1 (least recognisable) 
to 5 (most recognisable). Categories 1 and 2 contained 5 and 22 genes respectively, and so 
were combined in later analyses. The remaining categories had more than 33 genes per 
category. The ratio of observed loss-of-function DNMs to expected loss-of-function DNMs 
was calculated for each recognisability category, along with 95% confidence intervals from a 
Poisson distribution given observed counts.
We estimated the likelihood of obtaining the observed number of PTV DNMs under two 
models. Our first model assumed no haploinsufficiency, and mutation counts were expected 
to follow baseline mutation rates. Our second model assumed fully penetrant 
haploinsufficiency, and scaled the baseline PTV mutation expectations by the observed PTV 
enrichment in our known haploinsufficient neurodevelopmental genes, stratified by clinical 
recognisability into low (containing genes with our “low”, “mild” and “moderate” labels) 
and high categories. We calculated the likelihoods of both models per gene as the Poisson 
probability of obtaining the observed number of PTVs, given the expected mutation rates. 
We computed the Akaike’ s Information Criterion for each model and ranked them by the 
difference between model 1 and model 2 (ΔAIC).
Proportion of de novo mutations with loss-of-function mechanism
The observed excess of missense/inframe indel DNMs is composed of a mixture of DNMs 
with loss-of-function mechanisms and DNMs with altered-function mechanisms. We found 
that the excess of PTV DNMs within dominant haploinsufficient DD-associated genes had a 
greater skew towards genes with high intolerance for loss-of-function variants than the 
excess of missense DNMs in dominant non-haploinsufficient genes. We binned genes by the 
probability of being loss-of-function intolerant30 constraint decile and calculated the 
observed excess of missense DNMs in each bin. We modelled this binned distribution as a 
two-component mixture with the components representing DNMs with a loss-of-function or 
function-altering mechanism. We identified the optimal mixing proportion for the loss-of-
function and altered-function DNMs from the lowest goodness-of-fit (from a spline fitted to 
the sum-of-squares of the differences per decile) to missense/inframe indels in all genes 
across a range of mixtures.
The excess of DNMs with a loss-of-function mechanism was calculated as the excess of 
DNMs with a VEP loss-of-function consequence, plus the proportion of the excess of 
missense DNMs at the optimal mixing proportion.
We independently estimated the proportions of loss-of-function and altered-function. We 
counted PTV and missense/inframe indel DNMs within dominant haploinsufficient genes to 
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estimate the proportion of excess DNMs with a loss-of-function mechanism, but which were 
classified as missense/inframe indel. We estimated the proportion of excess DNMs with a 
loss-of-function mechanism as the PTV excess plus the PTV excess multiplied by the 
proportion of loss-of-function classified as missense.
Prevalence of developmental disorders from dominant de novo mutations
We estimated the birth prevalence of monoallelic developmental disorders by using the 
germline mutation model. We calculated the expected cumulative germline mutation rate of 
truncating DNMs in 238 haploinsufficient DD-associated genes. We scaled this upwards 
based on the composition of excess DNMs in the DDD cohort using the ratio of excess 
DNMs (n=1816) to DNMs within dominant haploinsufficient DD-associated genes (n=412). 
Around 10% of DDs are caused by de novo CNVs44,45, which are underrepresented in our 
cohort as a result of prior genetic testing. If included, the excess DNM in our cohort would 
increase by 21%, therefore we scaled the prevalence estimate upwards by this factor.
Mothers aged 29.9 and fathers aged 29.5 have children with 77 DNMs per genome on 
average21. We calculated the mean number of DNMs expected under different combinations 
of parental ages, given our estimates of the extra DNMs per year from older mothers and 
fathers. We scaled the prevalence to different combinations of parental ages using the ratio 
of expected mutations at a given age combination to the number expected at the mean cohort 
parental ages.
To estimate the annual number of live births with developmental disorders caused by DNMs, 
we obtained country population sizes, birth rates, age at first birth46, and calculated global 
birth rate (18.58 live births/1000 individuals) and age at first birth (22.62 years), weighted 
by population size. We calculated the mean age when giving birth (26.57 years) given a total 
fertility rate of 2.45 children per mother47, and a mean interpregnancy interval of 29 
months48. We calculated the number of live births given our estimate of DD prevalence 
caused by DNMs at this age (0.00288), the global population size (7.4 billion individuals) 
and the global birth rate.
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Extended Data
Extended Data Figure 1. 
Proportion of individuals with a de novo mutation (DNM) likely to be pathogenic. These 
only included individuals with protein altering or protein truncating DNMs in dominant or 
X-linked dominant developmental disorder (DD) associated genes, or males with DNMs in 
hemizygous DD-associated genes. The proportions given are for those individuals with any 
DNMs rather than the total number of individuals in each subset. Cohorts included in the 
DNM meta-analyses are shaded blue.
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Extended Data Figure 2. 
Phenotypic summary of genes without previous compelling evidence. Phenotypes are 
grouped by type. The first group indicates counts of individuals with DNMs per gene by sex 
(m: male, f: female), and by functional consequence (nsv: nonsynonymous variant, PTV: 
protein-truncating variant). The second group indicates mean values for growth parameters: 
birthweight (bw), height (ht), weight (wt), occipitofrontal circumference (OFC). Values are 
given as standard deviations from the healthy population mean derived from ALSPAC data. 
The third group indicates the mean age for achieving developmental milestones: age of first 
social smile, age of first sitting unassisted, age of first walking unassisted and age of first 
speaking. Values are given in months. The final group summarises Human Phenotype 
Ontology (HPO)-coded phenotypes per gene, as counts of HPO-terms within different 
clinical categories.
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Extended Data Figure 3. 
Phenotypic summary of individuals with de novo mutations in genes achieving genomewide 
significance. Phenotypes are grouped by type. The first group indicates counts of individuals 
with DNMs per gene by sex (m: male, f: female), and by functional consequence (nsv: 
nonsynonymous variant, PTV: protein-truncating variant). The second group indicates mean 
values for growth parameters: birthweight (bw), height (ht), weight (wt), occipitofrontal 
circumference (OFC). Values are given as standard deviations from the healthy population 
mean derived from ALSPAC data. The third group indicates the mean age for achieving 
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developmental milestones: age of first social smile, age of first sitting unassisted, age of first 
walking unassisted and age of first speaking. Values are given in months. The final group 
summarises Human Phenotype Ontology (HPO)-coded phenotypes per gene, as counts of 
HPO-terms within different clinical categories.
Extended Data Figure 4. 
Dispersion of de novo mutations and domains for each novel gene.a, CDK13, b, CHD4, c, 
CNOT3, d, CSNK2A1, e, GNAI1, f, KCNQ3, g, MSL3, h, PPM1D, I, PUF60, j, QRICH1, 
k, SET, l, SUV420H1, m, TCF20 and n, ZBTB18.
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Extended Data Figure 5. 
Effect of clustering by phenotype on the ability to identify genomewide significant genes.a, 
Comparison of P-values derived from genotypic information alone versus P-values that 
incorporate genotypic information and phenotypic similarity. b, Comparison of P-values 
from tests in the complete DDD cohort versus tests in the subset with seizures. Genes that 
were previously linked to seizures are shaded blue. c, Proportion of cohort with a de novo 
mutation (DNM) in a seizure-associated gene, stratified by whether seizure-affected status. 
Bars indicate 95% CI. d, Comparison of power to identify genomewide significant genes in 
probands with seizures, versus the unstratified cohort, at matched sample sizes.
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Extended Data Figure 6. 
Power of genome versus exome sequencing to discover dominant genes associated with 
developmental disorders. a, the number of genes exceeding genome-wide significance was 
estimated at three different fixed budgets (1 million (M) USD, 2M and 3M) and a range of 
relative sensitivities for genomes versus exomes to detect de novo mutations. The number of 
genes identifiable by exome sequencing are shaded blue, whereas the number of genes 
identifiable by genome sequencing are shaded green. The regions where exome sequencing 
costs 30-40% of genome sequencing are shaded with a grey background, which corresponds 
to the price differential in 2016. b, simulated estimates of power to detect loss-of-function 
genes in the genome at different cohort sizes, given fixed budgets.
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Extended Data Figure 7. 
Gene-wise significance of neurodevelopmental genes versus the expected number of 
mutations per gene. Points are shaded by clinical recognisability classification. Genes have 
been separated into two plots, one plot with genes for cryptic disorders with low, mild or 
moderate clinical recognisability, and one plot with genes for distinctive disorders with high 
clinical recognisability.
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Extended Data Figure 8. 
Stringency of de novo mutation (DNM) filtering. a, Sensitivity and specificity of DNM 
validations within sets filtered on varying thresholds of DNM quality (posterior probability 
of DNM). The analysed DNMs were restricted to sites identified within the earlier 1133 
trios15, where all candidate DNMs underwent validation experiments. The labelled value is 
the quality threshold at which the number of candidate synonymous DNMs equals the 
number of expected synonymous mutations under a null germline mutation rate. b, Excess 
of missense and loss-of-function DNMs at varying DNM quality thresholds. The DNM 
excess is adjusted for the sensitivity and specificity at each threshold.
Extended Data Figure 9. 
Enrichment of de novo mutations by consequence type, across RVIS functional constraint 
quantiles. A comparison of enrichment for RVIS values generated from ESP6500 data 
versus ExAC data is provided.
Extended Data Table 1
Phenotypes tested for association with having a pathogenic de novo mutation.
Category Phenotype Type Value 95% CI P-value
Post-natal
abnormal cranial MRI Odds ratio 1.365 1.125 – 1.656 0.002
feeding problems Odds ratio 1.176 1.01 – 1.369 0.039
neonatal intensive care Odds ratio 0.896 0.762 – 1.054 0.190
anticonvulsant drugs Odds ratio 0.582 0.246 – 1.377 0.270
Pre-natal
bleeding Odds ratio 0.892 0.714 – 1.114 0.346
maternal illness Odds ratio 0.908 0.764 – 1.079 0.278
maternal diabetes Odds ratio 0.787 0.504 – 1.229 0.341
abnormal scan Odds ratio 0.839 0.692 – 1.017 0.078
assisted reproduction Odds ratio 0.868 0.554 – 1.36 0.584
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Category Phenotype Type Value 95% CI P-value
increased nuchal translucency Odds ratio 1.432 0.903 – 2.271 0.126
Family history
consanguinity Odds ratio 0.234 0.138 – 0.397 8.0 x 10-11
similar phenotype parents Odds ratio 0.295 0.184 – 0.474 5.7 x 10-9
similar phenotype relatives Odds ratio 0.553 0.402 – 0.761 1.5 x 10-4
similar phenotype siblings Odds ratio 0.311 0.23 – 0.421 7.3 x 10-18
only patient affected Odds ratio 2.478 2.001 – 3.068 3.9 x 10-19
X-linked inheritance Odds ratio 0.839 0.436 – 1.613 0.752
Multiple births Beta 0.043 -0.058 – 0.144 0.403
History of pregnancy loss Beta -0.039 -0.155 – 0.078 0.516
Developmental milestones
first words Beta 0.205 0.081 – 0.328 0.001
walked independently Beta 0.125 0.016 – 0.235 0.025
sat independently Beta 0.050 -0.069 – 0.17 0.408
social smile Beta 0.072 -0.066 – 0.211 0.305
Growth
height Beta 0.008 -0.111 – 0.126 0.897
birthweight Beta -0.018 -0.135 – 0.098 0.756
OFC Beta -0.094 -0.215 – 0.026 0.125
weight Beta -0.331 -1.278 – 0.615 0.493
Age
age at assessment Beta 0.116 0.015 – 0.217 0.025
gestation Beta 0.079 -0.033 – 0.19 0.167
father's age Beta 0.137 0.027 – 0.247 0.015
mother's age Beta 0.108 -0.003 – 0.219 0.056
Other
phenotypic terms (n) Beta 0.104 0.004 – 0.203 0.041
autozygosity length Beta -0.185 -0.254 – -0.115 1.6 x 10-7
sex (male) Odds ratio 0.750 0.646 – 0.87 1.6 x 10-4
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Abbreviations
PTV Protein-Truncating Variant
DNM De Novo Mutation
DD Developmental Disorder
DDD Deciphering Developmental Disorders study
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Figure 1. 
Association of phenotypes with presence of likely pathogenic de novo mutations (DNMs). 
Association of phenotypes with presence of likely pathogenic de novo mutations (DNMs). a, 
Odds ratios for binary phenotypes. Positive odds ratios are associated with increased risk of 
pathogenic DNMs when the phenotype is present. P-values are given for a Fisher’ s Exact 
test. b, Beta coefficients from logistic regression of quantitative phenotypes versus presence 
of a pathogenic DNM. All phenotypes aside from length of autozygous regions were 
corrected for gender as a covariate. The developmental milestones (age to achieve first 
words, walk independently, sit independently and social smile) were log-scaled before 
regression. The growth parameters (height, birthweight and occipitofrontal circumference 
(OFC)) were evaluated as absolute distance from the median. c, Relationship between length 
of autozygous regions chance of having a pathogenic DNM. The regression line is plotted as 
the dark gray line. The 95% confidence interval for the regression is shaded gray. The 
autozygosity lengths expected under different degrees of consanguineous unions are shown 
as vertical dashed lines. n, number of individuals in each autozygosity group. d, 
Relationship between age of fathers at birth of child and number of high confidence DNMs. 
n, number of high confidence DNMs. e, Relationship between age of mothers at birth of 
child and number of high confidence DNMs. Error bars indicate 95% c.i. n, number of high 
confidence DNMs.
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Figure 2. 
Genes exceeding genome-wide significance. Manhattan plot of combined P-values across all 
tested genes. The red dashed line indicates the threshold for genome-wide significance (P < 
7 x 10-7). Genes exceeding this threshold have HGNC symbols labelled. De-identified 
realistic average (‘ composite’ ) faces were generated using previously validated software24 
from clinical photos from individuals with DNMs in the same gene, and are shown here for 
the six most-significantly associated genes. Confirmation of de-identification was performed 
by careful review by two experienced clinical geneticists. Each face was generated from 
clinical photos of more than ten children.
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Figure 3. 
Excess of de novo mutations (DNMs). a, Enrichment ratios of observed to expected loss-of-
function DNMs by clinical recognisability for dominant haploinsufficient 
neurodevelopmental genes as judged by two consultant clinical geneticists. Error bars 
indiciate 95% CI. b, Enrichment of DNMs by consequence normalised relative to the 
number of synonymous DNMs. c, Proportion of excess DNMs with loss-of-function or 
altered-function mechanisms. Proportions are derived from numbers of excess DNMs by 
consequence, and numbers of excess truncating and missense DNMs in dominant 
haploinsufficient genes. d, Enrichment ratios of observed to expected DNMs by pLI 
constraint quantile for loss-of-function, missense and synonymous DNMs. Counts of DNMs 
in each lower and upper half of the quantiles are provided. e, Normalised excess of observed 
to expected DNMs by pLI constraint quantile. This includes missense DNMs within all 
genes, loss-of-function including missense DNMs in dominant haploinsufficient genes and 
missense DNMs in dominant nonhaploinsufficient genes (genes with dominant negative or 
activating mechanisms). f, Proportion of excess missense DNMs with a loss-of-function 
mechanism. The red dashed line indicates the proportion in observed excess DNMs at the 
optimal goodness-of-fit. The histogram shows the frequencies of estimated proportions from 
1000 permutations, assuming the observed proportion is correct.
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Figure 4. 
Prevalence of live births with developmental disorders caused by dominant de novo 
mutations (DNMs). The prevalence within the general population is provided as percentage 
for combinations of parental ages, extrapolated from the maternal and paternal rates of 
DNMs. Distributions of parental ages within the DDD cohort and the UK population are 
shown at the matching parental axis.
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Table 1
Genes achieving genome-wide significant statistical evidence without previous compelling evidence for being 
developmental disorder genes. The numbers of unrelated individuals with independent de novo mutations 
(DNMs) are given for protein truncating variants (PTV) and missense variants. Counts of individuals in other 
cohorts are given in brackets if present. The P-value reported is the minimum P-value from the testing of the 
DDD dataset or the meta-analysis dataset. The subset providing the P-value is also listed. Mutations are 
considered clustered if the P-value from proximity clustering of DNMs is less than 0.01.
Gene Missense PTV P-value Test Clustering
CDK13 10 1 3.2 x 10-19 DDD Yes
GNAI1 7 (1) 1 2.1 x 10-13 DDD No
CSNK2A1 7 0 1.4 x 10-12 DDD Yes
PPM1D 0 5 (1) 6.3 x 10-12 Meta No
CNOT3 5 2 (1) 5.2 x 10-11 DDD Yes
MSL3 0 4 2.2 x 10-10 DDD No
KCNQ3 4 (3) 0 3.4 x 10-10 Meta Yes
ZBTB18 1 (1) 4 1.4 x 10-9 DDD No
PUF60 4 (1) 3 2.6 x 10-9 DDD No
TCF20 1 5 2.7 x 10-9 DDD No
SUV420H1 0 (2) 2 (3) 2.9 x 10-9 Meta No
CHD4 8 (1) 1 7.6 x 10-9 DDD No
SET 0 3 1.2 x 10-7 DDD No
QRICH1 0 3 (1) 3.6 x 10-7 Meta No
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